Valuation: Silence Therapeutics plc

Market Cap 418M 564M 488M 456M 787M 53.72B 799M 5.35B 2.1B 26.93B 2.12B 2.07B 89.01B P/E 2026 *
-20x
P/E 2027 * -17.8x
Enterprise Value 272M 368M 318M 297M 512M 34.98B 520M 3.48B 1.37B 17.53B 1.38B 1.35B 57.96B EV / Sales 2026 *
108x
EV / Sales 2027 * 48.9x
Free-Float
69.36%
Yield 2026 *
-
Yield 2027 * -
1 day+1.96%
1 week+13.92%
Current month+13.92%
1 month+17.73%
3 months+71.94%
6 months+151.58%
Current year+96.55%
1 week 10.32
Extreme 10.32
12.3
1 month 8.91
Extreme 8.91
12.3
Current year 4.19
Extreme 4.19
12.3
1 year 4.19
Extreme 4.19
12.3
3 years 1.97
Extreme 1.97
27.72
5 years 1.97
Extreme 1.97
27.72
10 years 1.97
Extreme 1.97
35
Manager TitleAgeSince
Chief Executive Officer 72 01/12/2025
Director of Finance/CFO 54 01/02/2022
Chief Tech/Sci/R&D Officer - 01/01/2021
Director TitleAgeSince
Director/Board Member 63 21/06/2018
Chairman 72 01/01/2004
Director/Board Member 65 05/05/2025
Date Insider Type Main position Quantity % Market Cap.
7/6/26 A Sell 865,112 0.6105%
1/2/26 A Free

Chief Financial Officer

375,000 0.2646%
1/2/26 A Free

Director

90,000 0.0635%
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+13.92%+122.12%+116.09% 564M
+0.99%+1.78%+4.07%+16.73% 49.47B
+3.71%+9.40%+486.98%+592.14% 43.61B
+2.70%+1.57%+33.39%+8.85% 39.29B
+5.60%+10.21%+16.76%+85.72% 39.6B
+2.21%+6.75%+21.31%+53.37% 32.43B
+2.23%+4.71% - - 16.84B
+0.97%+2.35%+37.75%+126.84% 16.49B
-0.11%+2.41%+6.24%+18.87% 14.01B
+0.75%+15.04%+78.59%+30.30% 12.77B
Average +2.10%+7.08%+89.69%+116.55% 26.51B
Weighted average by Cap. +2.54%+6.11%+104.30%+140.73%

Financials

2026 *2027 *
Net sales 2.51M 3.39M 2.93M 2.74M 4.73M 323M 4.8M 32.15M 12.62M 162M 12.74M 12.46M 535M 3.47M 4.68M 4.05M 3.78M 6.52M 445M 6.63M 44.36M 17.41M 223M 17.58M 17.19M 738M
Net income -50.4M -68.02M -58.84M -54.94M -94.8M -6.47B -96.31M -645M -253M -3.24B -255M -250M -10.73B -84.8M -114M -98.99M -92.44M -160M -10.89B -162M -1.08B -426M -5.46B -430M -420M -18.05B
Net Debt -146M -197M -170M -159M -274M -18.74B -279M -1.87B -732M -9.39B -739M -723M -31.05B -249M -336M -290M -271M -468M -31.95B -475M -3.18B -1.25B -16.02B -1.26B -1.23B -52.95B
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
88
Date Price Change Volume
07/08/26 $11.95 +1.96% 316,885
06/08/26 $11.72 +4.27% 252,799
05/08/26 $11.24 +0.63% 452,234
04/08/26 $11.17 +4.59% 518,643
03/08/26 $10.68 +1.81% 536,744
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
11.95USD
Average target price
29.17USD
Spread / Average Target
+144.07%

Quarterly revenue - Rate of surprise